Products

KIEU HOANG
- Chairman, CEO of Rare Antibody Antigen Supply Inc., California, USA 
- Former Vice Chairman of Shanghai RAAS Blood Products Co. Ltd., Shanghai, China
- Former Vice Chairman of the Board of Bio Products Laboratory, Ltd., Elstree, England 
- Former Board Member of Biotest, A.G., Frankfurt, Germany 
- Founder, Chairman, President & CEO of RAAS Nutritionals, LLC., Thousand Oaks, CA, USA 
- Founder, Chairman, President & CEO of Kieu Hoang Winery, LLC., Napa, CA, USA 
- Founder, Chairman, President & CEO of Hummingbird Nest, LLC., Santa Susana, CA, USA 

- Founder, Chairman, President & CEO of KHKMY, LLC., Thousand Oaks, CA, USA 

• 7 patents granted in the United States of America. 34 patents granted internationally. including Australia, Australia, Brazil, Canada, Egypt, EPO, Germany, France, Italy, Netherlands, United Kingdom, GCC, Iran, Republic of Korea, Mexico, Malaysia, Philippines, Russian Federation, Singapore, Thailand, Taiwan, Vietnam, etc.

• 85 Pending patent applications in United States of America. 75 patents have been applied including new found proteins in grape, soy, ginkgo, egg, etc.
• Highest level of triglycerides were found in red or green hot pepper, second highest level of triglycerides were found in soy beans (edamame) among 100 tested items.
• The highest level of high density lipoprotein were found in Kieu Hoang™ Wines, AFCC TM and AFOD TM among 100 tested items.
• 55 new found KH Good Proteins from KH 1 to KH55 , their sequences, their functions and their applications (PCT/US2013/024118).
• KH Good Healthy 55 new found cells.
• Self generated power and water plant by using sun, wind ,rain water and triangle shaped lithum battery and drive through power supply station (PCT/US2013/024062).
• 134 new found proteins in soy.
• 134 new found KH Good Healthy cells in soy.

About the founder and history of RAAS Nutritionals, LLC. 

Kieu Hoang, who found and lead Shanghai RAAS (the No. 4 innovative company in the world by Forbes magazine), RAAS and RAAS Nutritionals. LLC., was born in Vietnam. He began his professional career in the USA in 1975 at Abbott Reference Laboratories, the current Location of AMGEN Facilities in Newbury Park, CA. At that time he managed the first FDA approved testing laboratory for plasma industry, mostly testing for Hepatitis B. In 1980 he founded Rare Antibody Antigen Supply Inc. and began to acquire a number of plasma centers in the United States of America. A central Laboratory had been established at Agoura Hills, California licensed by State of California and FDA In 1987, Mr. Hoang ventured into China, a country with largest population in the whole world. Through foreign affairs andunder the leadership of Mayor Zhu ZongJi, Mr. Hoang was able to partner with Shanghai Blood center at a time where noforeign company was allowed to own 50% of a Chinese company. In 1992, after several years’ construction and distribution foreign Human Albumin, Shanghai RAAS was established and began selling its own Human Albumin AlbuRAAS® and plasma derived medicine. In 2005, Kieu Hoang returned to Vietnam after thirty years. He organized numerous charities events to help the people in need. He donated 5,000 homes, built roads & bridges, temples and schools. He also partnered with World Bank to provide health insurance for the people in need, provide food and resources for flood victims, HIV Education andnumerous culture events to help attract tourists into their provinces. He funded efforts to promote agriculture and animal husbandry. | Visit us: www.kieuhoangcharities.com |

Since 2010 Mr. Hoang has focused on his research in plasma, healthcare, animal& plant care and energy projects. Through his studies on different foods and plants, he has come across numerous findings. Studying Red wine caught his attention. A small grape has 5000 more genes than a human being. In his research, his wine showed the highest level of High Density Lipoprotein among more than 100 items tested items. In 2012 he traveled to the world famous Napa Valley, California and worked with experts to establish Kieu Hoang Winery.

Achievements:

Design and perform rheopheresis of Abbott Laboratories to screen for plasma donors who have hepatitis B antigen high titer. (1980 - 1985).

Design and perform compliment fixation test to confirm the level of hepatitis B antigen for supply in the production of hepatitis B vaccine by MERCK SHARP & DOHME CORP. (1980 – 1985).

Design and perform radioimmunoassay parallel using WHO standards for hepatitis B antibody from qualified donors who have been vaccinated with hepatitis B vaccine for supply to Merck, Cutter, Alpha, Bayer, Biotest, Abbott, Baxter, Behring Werke and Kabi Pharmacia for the production of hepatitis B antibody immunoglobulin. (1980 – 1990).

Design and perform gel method to select high titer tetanus antibody who have been vaccinated with tetanus vaccine for supply to Merck, Cutter, Alpha, Bayer, Biotest, Abbott, Baxter, Behring Werke and Kabi Pharmacia for the production of hepatitis B antibody immunoglobulin. (1980 – 1990).

Design and perform ELISA enzyme link assay to select the cytomegalovirus high titer plasma for production of cytomegalovirus immunoglobulin for use in kidney transplants and supply to Biotest in Germany and Green Cross in Japan. (1980 – 1990).

Design and perform ELISA enzyme link assay to select the varicella zoster high titer plasma for production of varicella zoster immunoglobulin for use in children with chickenpox and supply to Biotest in Germany and Green Cross in Japan. (1980 – 1990).

Design and perform anti-D antibody testing and collect high titer antibody plasma to produce Rho(D) immune globulin to supply to Ortho. (1980 – 1990).

Design and perform a method to identify HIV antibodies in hepatitis B antibody powder to supply to Biotest in Germany to treat AIDS patients in the early stage. (1985 – 1987).

Clinical Experience: 

Sponsor, protocol design and Principal Investigator:

*COVlD-19 "Efficacy of novel functional food supplements based on grape, soy, edamame and rice in the prevention, treatment and cure of COVID-19 and 315 viruses and bacteria, including 116 other viruses and bacteria and 198 SARS-CoV-2 mutation and non-otherwise specified viruses and bacteria (NOS).”

*HBV "A Prospective, Open-label, Observational Study of The Efficacy of Kunamin (a grape derived supplement US Patent US 10,195,243 82) on Subjects with Chronic Hepatitis B. These HBV subjects may have concomitant diabetes mellitus type 2 (DM ll), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition."

*HCV "A Prospective, Open-label, Observational Study of The Efficacy of Kunakin a soybean and rice derived supplement U.S. Patent Application Serial No. 141979,697 and No. 62/304,4341 on Subjects with Chronic Hepatitis C. These HCV subjects may have concomitant diabetes mellitus type 2 (DM ll), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition."

*Efficacy of novel functional food supplements based on grape, soy, edamame and rice in the treatment, cure and prevention of underlying hypercholesterolemia, atherosclerosis and thrombosis in COVID-19 patients and 92 other viruses and bacteria including 198 non-otherwise specified (NOS) viruses and bacteria mutations. These subjects may have concomitant obesity, hypertension, chronic kidney disease and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of Kunakinade® (a non-GMO soybean derived supplement U.S. Patent Application Serial No. 14/979,697 and No. 62/304,434) on Subjects with Chronic Kidney Disease (CKD) who eGFR has not reached 60l/m. 

*A Prospective, Open-label, Observational Study of The Efficacy of Kunamin® (a non-GMO grape seed and grape skin extracts supplement) on Subjects with Pre-diabetes and Diabetes Mellitus. These subjects may have concomitant obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

Sponsor & Protocol Design:

*The invention relates to RAAS Nutritionals food functional dietary supplements derived from grape (vitis vinifera) and rice (Oryza sativa) for prophylaxis and therapeutic treatment of human immunodeficiency virus (HIV) virus namely KH Care HIV™

* Study Title: A Prospective, Open-label, Observational Study of The Efficacy of KH CARE BREAST™ (a grape and rice derived supplement US Patent US 10,195,243 B2) on Subjects with breast cancer (all cell types). These breast cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

*A Prospective, Open-label, Observational Study of The Efficacy of Kunakinext® (a non-GMO soybean derived supplement U.S. Patent Application Serial No. 14/979,697 and No. 62/304,434) on Subjects with Kidney Cancer who WILL RESPOND with it and Kunakinmin® (U.S. Patent Application Serial No. 62/096,813; 62/096,816 and 62/096,824) for those patients who WILL NOT RESPOND to Kunakinext®

* A Prospective, Open-label, Observational and Third Phase Clinical Study of The Efficacy of Kunakin® (a non-GMO soybean, Kieu Hoang wine and rice derived functional food dietary supplement U.S. Patent Application Serial No. 14/979,697 and No. 62/304,434, US Patent US 10,195,243 B2) on COVID-19 Subjects with underlying Prostate Cancer and to Stop and Prevent the Progression of Prostate Cancer.

* A Prospective, Open-label, observational Study of The Efficacy of KH Care Brain™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Brain Tumors (any type and stage). These brain tumor subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, observational Study of The Efficacy of KH Care Colon™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Colorectal Cancer. These Colorectal Cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, observational Study of The Efficacy of KH Care Leukemia™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Leukemia, any type. These leukemia subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of KH Care Lungs™ (a combination every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Lung Cancer, all types. These lung cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, observational Study of The Efficacy of KH Care Lymphoma tm (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Lymphoma, any type. These lymphoma subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of KH Care Alzheimers™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Alzheimer’s Disease, any stage. These Alzheimer’s Disease subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of Kunakinade® (a non-GMO soybean derived supplement) on Subjects with Zika Virus Disease. These Zika Virus Disease subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of KH Care Autism™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Autism Spectrum Disorder. These Autism subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, observational Study of The Efficacy of KH Care Liver™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Primary Liver Cancer (any type). These liver cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of KH Care Pancreas™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Pancreatic Cancer (any type and stage). These pancreatic cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

* A Prospective, Open-label, Observational Study of The Efficacy of KH Care Skin™ (a combination of every component of the grape derived supplement, US Patent US 10,195,243 B2) on Subjects with Skin Cancer (any type and stage). These skin cancer subjects may have concomitant diabetes mellitus type 2 (DM II), obesity, hypertension, chronic kidney disease, and/or hypercholesterolemia, and they are on stable standard therapy/drug for the respective condition.

Award: 

Business Man of the Year, Awarded by Congress (2003 & 2005)

 

OMER KUCUK, MD, FACN

Medical and Clinical Advisor, RAAS Nutritionals, LLC.

• Dr. Kucuk earned his medical degree at Hacettepe University Medical School in Ankara, Turkey. He conducted a residency and fellowship at St. Francis Hospital in Evanston, Illinois, and a hematology and oncology fellowship at Northwestern University Medical School in Chicago. Before joining the medical staff at Wayne State University, Dr. Kucuk served as professor and researcher at the University of Hawaii’s John A. Burns School of Medicine in Honolulu.

• Omer Kucuk, MD, conducted the first clinical trials to show the benefits of soy and lycopene supplements in prostate cancer treatment. He is a Professor in Hematology and Medical Oncology at Emory University’s Winship Cancer Institute.

• Dr. Kucuk came to Emory Winship from the Karmanos Cancer Center at Wayne State University in Detroit where he was a professor and co-leader of the population sciences and prevention program and member of genitourinary and head and neck cancer multidisciplinary groups.

• Dr. Kucuk has more than 250 peer-reviewed publications, review articles and book chapters to his credit, and he is on the editorial boards of numerous publications, including the Cancer Epidemiology, Biomarkers and Prevention and Cancer Epidemiology.

• Nutrition and cancer is Dr. Kucuk’s primary research focus, and he has published extensively on various nutrients in combination with chemotherapy and radiation. Dr. Kucuk has been conducting clinical trials with lycopene and soy isoflavones in combination with standard therapy for prostate cancer since 1995. He is also investigating the effects of micronutrients and phytochemicals on biomarkers of cell growth, differentiation, inflammation and oxidative stress in a variety of cancers.

 

Dr. PAUL A. IMBACH, MD

Medical and Clinical Advisor for Hematology and Immunology, RAAS Nutritionals, LLC.

• Habilitation in Pediatrics at the University of Berne 1983 and at University of Basel 1991.

• Professor in Pediatrics and Pediatric Oncology/Hematology, Medical Faculty, University of Basel 1993.

• Dean of Education and Head of Curriculum Reform Medical Faculty, University of Basel (1997 2002).

• Current: Professor Emeritus.

• Clinical leadership and research in the field of pediatric hematology oncology and in immunology, especially therapeutic antibody therapy.

• Initiation and leadership of autologous and allogeneic pediatric stemcell transplantation at the children hospitals of the university Bern and Basel.

• Performance in scholarship and teaching as full professor

• Scientific development and research in both clinical and academic settings

• Tutorials, supervision of doctoral theses (n=9)

• Evaluation of promotion applications to full professors for universities in Switzerland, Germany, USA, Canada and Near East

• Evaluation/Review of grant applications in different organisation worldwide

• Development of new forms of medical curriculum as dean of education at the medical faculty of the University of Basel

• Chair of the review committee of the Swiss Cancer League, section Basel 

•  Organisation and Coordinator of the Swiss Pediatric Oncology Group

• Principal investigator of many local and cooperative international clinical studies.

• Local Education of pediatric Oncology in Minsk, Bela Russia, after the Tchernobyl catastophy.

• Founder an Cair /Principal Investigator of the Intercontinental Cooperative ITP Studies ICIS group (www.itpbasel.ch).

• Over 400 scientific publications.

• Textbook writer of Pediatric Oncology, Springer: 3rd edition in English and German with 38'000 downloads.

• Contribution to textbooks in Hematology, Oncology and Immunology, (especially in antibody therapies)

• Editor of the Springer book 2018: Antibody Therapy: Substitution Immunomodulation Immune Therapy.

• Invited speaker at congresses, meetings, seminars nationally and internationally with over 380 lectures on all continents.

  

LUIS GALINDO-MENDOZA, MD, Ph.D.

International Medical Director, RAAS Nutritionals, LLC.

• Chairman, Department of Artificial Nutrition and Attending Surgeon, Department of General Surgery, "La Raza" Medical Center, Mexican Institute of Social Security from March 1989 to 2014. Professor of General Surgery, School of Medicine at the Universidad Nacional Autónoma de México from 1994 to 2014

• Coordinator, Mastership Degree in Clinical Nutrition, Anáhuac University, North Campus since 2004. Instructor Trainer, National Association for Underwater Instructors (scuba diving).

• Medical Degree, School of Medicine at the Universidad Nacional Autónoma de México, 1978 to 1983.

• Medical Specialty in General Surgery, "La Raza" Medical Center, Mexican Institute of Social Security, 1985 to 1988, Certified, Mexican Board of General Surgery, 1988. Sub-Specialty in Biliary-Pancreatic Surgery, National Medical Center, Mexican Institute of Social Security, 1988 to 1989.

• Master’s Degree, Clinical Nutrition, Anahuac University, Mexico, 2004 to 2005. PhD in Health Sciences, Anahuac University, Mexico, 2017.

• Memberships: American College of Surgeons, Mexican Association of General Surgery, American Society for Parenteral and Enteral Nutrition, European Society for Clinical Nutrition and Metabolism, International Association for Surgical Metabolism and Nutrition, Obesity Society, Academy of Nutrition and Dietetics, Société Internationale de Chirurgie and Society of Critical Care Medicine.

• Honors and Family: President of the Mexican College of Clinical Nutrition and Nutritional Therapy in 1998-1999. He’s married to the RD Cecilia Aguilar-Paulín and is father of Samuel, who is 10 years-old.  

  

ROBERT BLACKMON
Vice President and Head of Regulatory Affairs Compliance for RAAS Group Companies, including RAAS Nutritionals, LLC. 

• Mr. Blackmon is licensed to practice law in California and Virginia.

• Mr. Blackmon received a degree in Mechanical Engineering from Clemson University. He worked as an Aerospace Engineer for the U.S. Navy in NAS Alameda, California. Mr. Blackmon then transferred to the U.S. Patent Office to work as a Patent Examiner.  He went on to receive a law degree from George Mason University and received his license to practice law in Virginia in 1993. In 1995, he was successfully registered as a Patent Attorney. And in 2019, Mr. Blackmon received his license to practice law in California.

• He has been working for RAAS Group company since 2018. In support of his Regulatory Affairs compliance position, Mr. Blackmon has successfully completed a number of FDA courses including GMP Part 111, GMP Part 117, HACCP, as well as Food and Supplement labeling.

×

INQUIRIES

I agree to my email being stored and used to receive the newsletter.